Oncogenic CARD11 mutations in human diffuse large B cell lymphoma.
Authors:
Lenz, G Davis, RE Ngo, VN Lam, L George, TC Wright, GW Dave, SS Zhao, H Xu, W Rosenwald, A Ott, G Muller-Hermelink, HK Gascoyne, RD Connors, JM Rimsza, LM Campo, E Jaffe, ES Delabie, J Smeland, EB Fisher, RI Chan, WC Staudt, LM
Citation:
Lenz G, etal., Science. 2008 Mar 21;319(5870):1676-9. doi: 10.1126/science.1153629. Epub 2008 Mar 6.
Diffuse large B cell lymphoma (DLBCL) is the most common form of non-Hodgkin's lymphoma. In the least curable (ABC) subtype of DLBCL, survival of the malignant cells is dependent on constitutive activation of the nuclear factor-kappaB (NF-kappaB) signaling pathway. In normal B cells, antigen receptor-induced NF-kappaB activation requires CARD11, a cytoplasmic scaffolding protein. To determine whether CARD11 contributes to tumorigenesis, we sequenced the CARD11 gene in human DLBCL tumors. We detected missense mutations in 7 of 73 ABC DLBCL biopsies (9.6%), all within exons encoding the coiled-coil domain. Experimental introduction of CARD11 coiled-coil domain mutants into lymphoma cell lines resulted in constitutive NF-kappaB activation and enhanced NF-kappaB activity upon antigen receptor stimulation. These results demonstrate that CARD11 is a bona fide oncogenein DLBCL, providing a genetic rationale for the development of pharmacological inhibitors of the CARD11 pathway for DLBCL therapy.